Furthermore, there are indications that CDK5RAP2 levels can influence cancer treatment response since CDK5RAP2 knockdown breast cancer cell lines display increased resistance towards paclitaxel and doxorubicin in a study by Zhang et al [30]. This evidence concerns the gene CDK5RAP2 and breast cancer.